This study evaluates the efficacy and the safety of the HIFU for the treatment of breast fibroadenoma.
Echopulse is specially designed, manufactured and CE marked for treating breast fibroadenoma. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to 85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted area.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
HIFU Under ultrasound guidance
Bellevue Hospital Center
New York, New York, United States
COMPLETEDNew York Columbia University Medical Center
New York, New York, United States
COMPLETEDMontefiore-Einstein Center for Cancer Care
New York, New York, United States
COMPLETEDPain level assessment
visual analog scale
Time frame: 12 Months
Anxiety level assessment
visual analog scale
Time frame: 12 Months
Volume assessment
Ultrasound measurement
Time frame: 12 Months
The short (6-item) version of the State-Trait Anxiety Inventory (STAI)
Time frame: inclusion visit (V0), Day 2/3, Day 7, 6 months, 12 months
Palpability of the breast fibroadenoma
Physician clinical examination
Time frame: inclusion visit (V0), Day 2/3, Day 7, 6 months, 12 months
Freedom from additional procedures for fibroadenoma of the breast
Physician assessment concerning the need of additional procedures
Time frame: Day 2/3, Day 7, 6 months, 12 months
Patient satisfaction
Self assessment satisfaction questionnaire
Time frame: Month 6 and Months 12
Safety endpoints include adverse events (AEs) and serious adverse events (SAEs) occurring at any time during the trial.
Assessment and capture of adverse events
Time frame: Day 0, Day 2/3, Day 7, 6 months, 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Virginia Health system
Charlottesville, Virginia, United States
RECRUITING